NCT04898257View on ClinicalTrials.gov

Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

October 8, 2020

Study Completion Date

November 25, 2020

Conditions
IBS - Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Multistrain probiotic

After completion of screening phase, during baseline visit, eligible patients will be assigned to Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day on an empty stomach (30 minutes before breakfast and 30 minutes before dinner).

Trial Locations (1)

00168

Fondazione Policlinico Gemelli, Roma

All Listed Sponsors
lead

Larena SAS

INDUSTRY

NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients | Biotech Hunter | Biotech Hunter